Haleon Selects Salesforce Agentforce Life Sciences Cloud for Customer Engagement to Improve Engagement with Pharmacies and Healthcare Professionals with AI
8.10.2025 15:07:00 EEST | Business Wire | Press release
Haleon plc (LSE/NYSE:HLN), a leading global consumer company that specialises in everyday health and Salesforce (NYSE:CRM), the world’s #1 AI CRM, today announced that Haleon will leverage Salesforce to drive more effective engagement with pharmacies and healthcare professionals worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251008924109/en/
A pharmacist advises a consumer on the purchase of Haleon’s Otrivin nasal mist.
Haleon has chosen Salesforce Life Sciences Cloud for Customer Engagement, Data Cloud, and Agentforce to support its 4,500-strong sales force globally. The AI-powered solution will enable the global consumer healthcare company to have more productive customer interactions, deepening its relationships with pharmacists and healthcare professionals around the world. This should serve to benefit millions of consumers globally by giving more people better access to everyday healthcare products.
With Salesforce, Haleon’s sales representatives will spend less time on administrative tasks and have access to data-driven insights on consumer demographics, shopping trends, and point-of-sale marketing. This will enable Haleon’s sales representatives to focus their efforts on value-add activities such as bespoke activation plans for their customers.
Additionally, Haleon, maker of category leading brands like Sensodyne, Voltaren, and Centrum, will serve as a design partner for Salesforce Life Sciences Cloud for Customer Engagement. In this role, Haleon will influence the development of Salesforce’s life sciences solutions to further address the specific needs of the consumer health industry, including by supporting product availability, shelf-life management, promotions, and inventory management across global retail and online channels.
“We are excited to partner with Salesforce to bring more effective, data-driven insights to our customers. This selection of Life Sciences Cloud and Agentforce will enable pharmacists and healthcare professionals to more efficiently deliver better everyday health to millions of people all around the world,” commented Claire Dickson, Chief Digital and Technology Officer at Haleon.
Dickson continued, “We are also delighted to advise Salesforce on the development of the consumer health capabilities of the platform. We are committed to shaping the future of our industry and look forward to impacting the development of tools that will help support the growth of all our categories.”
“Haleon's adoption of our next-generation Life Sciences Cloud for Customer Engagement and Agentforce will reimagine how the consumer health industry engages with pharmacies and HCPs through real-time insights and trusted AI,” said Frank Defesche, General Manager of Life Sciences at Salesforce. "Their insights ensure we’re meeting the complex, specific needs of the consumer healthcare industry without having to customize solutions - all while promoting greater productivity, innovation, and wellness."
Notes to Editors:
Learn more:
- Register for Dreamforce to see the launch in-action
- Discover how Salesforce is leading the next era of Life Sciences transformation
- Hear from some of the 70+ organizations who selected Life Sciences Cloud
- Get a sneak peek of the Life Sciences Cloud roadmap and transition framework
- Read about Salesforce’s open ecosystem and robust partner network
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com
About Salesforce
Salesforce helps organizations of any size reimagine their business for the world of AI. With Salesforce's trusted platform and Agentforce, organizations can bring humans together with agents to drive customer success—powered by AI, data, and action. With its long-standing history powering the healthcare industry, Salesforce continues to be invested in driving healthier outcomes for pharma and medtech organizations. Visit www.salesforce.com for more information.
Order Management is expected to be available as a part of Life Sciences Cloud for Customer Engagement starting October 2026. Any unreleased services or features referenced here are not currently available and may not be delivered on time or at all. Customers should make their purchase decisions based upon features that are currently available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251008924109/en/
Contacts
Haleon PR Contact:
Gemma Thomas
gemma.x.thomas@haleon.com
Salesforce PR Contact:
Maha Neouchy
pr@salesforce.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International Publishes Inaugural Taskforce on Nature-related Financial Disclosures Report22.9.2026 12:00:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today published its inaugural Taskforce on Nature-related Financial Disclosures (TNFD) Report, providing shareholders and other stakeholders with its most comprehensive assessment to date of nature-related dependencies, impacts, risks, and opportunities (DIROs) across the company’s global value chain. As an early adopter of the TNFD recommendations, PMI’s TNFD Report supports the company’s efforts to sharpen its understanding of how natural capital considerations influence business resilience and decision-making over time, while contributing to emerging practices in nature-related disclosure. Nature is one of the six strategic priorities that define PMI’s Value Plan 2030+, the company’s framework for long-term sustainable value creation, alongside Consumers, Circularity, Climate, Our Workforce, Workers in Our Value Chain. The TNFD Report follows the release of PMI’s 2025 Climate Transition Plan, prepared in line with the TCFD framework,
ROSHN Group Expands Foreign Real Estate Ownership Opportunities Across Saudi Arabia22.9.2026 10:00:00 EEST | Press release
ROSHN Group, Saudi Arabia’s leading master developer and a PIF company, is supporting a new chapter for international participation in the Saudi real estate market, as the Kingdom’s regulations governing non-Saudi property ownership create new opportunities for eligible international buyers and investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922356820/en/ ROSHN Group offers world-class living and investment opportunities, including SEDRA Curated Collection in Riyadh (Photo: AETOSWire) Thousands of non-Saudi buyers have registered interest with ROSHN Group since the regulatory updates, reflecting the growth and diversification of the Kingdom’s real estate sector by attracting new sources of demand and investment, while complementing the continued delivery of homes and communities for Saudi citizens. For ROSHN Group, this creates an opportunity to broaden access to its growing portfolio while expanding housing sup
Regnology Research Maps Route From AI Pilots to Production in Regulatory Reporting22.9.2026 09:33:00 EEST | Press release
Regnology, a leader in regulatory, risk, tax and finance reporting technology, today published “The Agentic Gap: From Control to Intelligence in Regulatory Reporting”, accompanied by a video foreword from Chief Executive Officer Rob Mackay. The global study sets out where agentic AI can take on meaningful operational load today, and gives institutions a practical roadmap from isolated pilots into scaled production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921218912/en/ The research finds an industry already mobilizing. 87% of respondents are exploring, piloting or embedding AI in operations, and only 13% report no current plan. The constraint is a shared one. Embedded, production-level use sits between 8% and 15% at every institution tier, and 16% of respondents overall have reached it, with 89% of financial institutions yet to get there. Resources buy experimentation, but production use is earned on the same terms
Bureau Veritas Confirms LEAP | 28 Ambition, Upgrades Total Revenue Growth to Double-Digit in 2027 – 2028 1 and Targets EUR1 Billion Revenue in AI-Driven Markets and Services by 203022.9.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): CAPITAL MARKETS DAY 2026 Today, Bureau Veritas hosts its Capital Markets Day. The Company will present an update on the progress of its LEAP | 28 strategy, building on three years of successful execution. › 2024-2026 achievements: Proven track record: mid-to-high single-digit organic revenue growth (7-8%) delivered across 2023–2026e2, with 115 basis points of adjusted operating margin improvement3; Portfolio transformation on track: c. 21.0% of the portfolio rotated since LEAP | 28 launch, with EUR1.2 billion of revenue acquired, sold or to be exited through 24 acquisitions, 4 divestments and 1 exit; New operating model: the active portfolio management delivered allowed the Company to create a new operating model that simplifies its growth algorithm. Combined with a simplified organization with four divisions and ten Product Lines, it sharpens Bureau Veritas’ position as a focused multi-specialist Company; Driving growth and profitability: through Portfolio
OPM Biosciences Launches Integrated Cell Culture Media-to-Manufacturing Platform for Biosimilar Development22.9.2026 08:00:00 EEST | Press release
OPM Biosciences, a cell culture media and bioprocess solutions company, today announced two new offerings that extend its OPM-CHO™ platform into biosimilar development and manufacturing: the Biosimilar Media Optimization Service and the Sureness™ Biosimilar Platform. Cell culture media can significantly influence cell growth, productivity, and critical quality attributes (CQAs), making media strategy an important component of biosimilar process development. OPM-CHO, the company’s portfolio of chemically defined cell culture media for CHO-based biomanufacturing, has supported more than 390 molecules in clinical and commercial stages worldwide, including biosimilars. Across 35 side-by-side evaluations, OPM-CHO media delivered an average titer improvement of 96% over each program’s original media combinations*. In separate internal studies, OPM-CHO media demonstrated lot-to-lot variability below 5%.* As patent expirations create new opportunities for biosimilar development, achieving a pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom